Search research articles
Contact Us
Filters
Showing results (231-240 of 253) with videos related to
Page
of 26
Sort By:
The Lancet. Infectious Diseases
|
August 19, 2017
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial
Xavier Forns, Samuel S Lee, Joaquin Valdes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 28, 2023
A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds
Lisa Usdan, Sohil Patel, Hector Rodriguez, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
July 12, 2019
Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infection
D Viasus, P Puerta-Alcalde, C Cardozo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 30, 2019
Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease
Edward Gane, Fred Poordad, Neddie Zadeikis, et al.
Journal of Chemotherapy (Florence, Italy)
|
November 6, 2003
Clinical characteristics and response to newer quinolones in Legionella pneumonia: a report of 28 cases
J Santos, L Aguilar, E García-Méndez, et al.
Antimicrobial Agents and Chemotherapy
|
December 17, 2014
Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis
Stefan Zeuzem, Vicente Soriano, Tarik Asselah, et al.
Antiviral Therapy
|
April 6, 2013
Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results
Stefan Zeuzem, Tarik Asselah, Peter Angus, et al.
Journal of Hepatology
|
March 20, 2018
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis
Massimo Puoti, Graham R Foster, Stanley Wang, et al.
Hepatology (Baltimore, Md.)
|
November 21, 2017
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure
Fred Poordad, Stanislas Pol, Armen Asatryan, et al.
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia
|
February 27, 2018
Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy
J Mensa, J Barberán, A Soriano, et al.
Page
of 26
Search research articles
Search
Showing results (231-240 of 253) with videos related to
Sort By:
Page
of 26
The Lancet. Infectious Diseases
|
August 19, 2017
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial
Xavier Forns, Samuel S Lee, Joaquin Valdes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 28, 2023
A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds
Lisa Usdan, Sohil Patel, Hector Rodriguez, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
July 12, 2019
Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infection
D Viasus, P Puerta-Alcalde, C Cardozo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 30, 2019
Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease
Edward Gane, Fred Poordad, Neddie Zadeikis, et al.
Journal of Chemotherapy (Florence, Italy)
|
November 6, 2003
Clinical characteristics and response to newer quinolones in Legionella pneumonia: a report of 28 cases
J Santos, L Aguilar, E García-Méndez, et al.
Antimicrobial Agents and Chemotherapy
|
December 17, 2014
Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis
Stefan Zeuzem, Vicente Soriano, Tarik Asselah, et al.
Antiviral Therapy
|
April 6, 2013
Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results
Stefan Zeuzem, Tarik Asselah, Peter Angus, et al.
Journal of Hepatology
|
March 20, 2018
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis
Massimo Puoti, Graham R Foster, Stanley Wang, et al.
Hepatology (Baltimore, Md.)
|
November 21, 2017
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure
Fred Poordad, Stanislas Pol, Armen Asatryan, et al.
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia
|
February 27, 2018
Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy
J Mensa, J Barberán, A Soriano, et al.
Page
of 26